about
VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancerRecent advances in the field of anti-cancer immunotherapyPET probes beyond (18)F-FDGCannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effectComparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells.Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigmCannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature surveyProtein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expressionContinuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer.Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan.Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future DirectionsIdentification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinomaOptimal management of bone metastases in breast cancer patients.Increased levels of active c-Src distinguish invasive from in situ lobular lesions.Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells."Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?Biological signalling activity measurements using mass spectrometry.Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience.The mTOR protein as a target in thyroid cancer.Array-based pharmacogenomics of molecular-targeted therapies in oncology.mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade.Crosstalk with insulin and dependence on PI3K/Akt/mTOR rather than MAPK pathways in upregulation of basal growth following long-term oestrogen deprivation in three human breast cancer cell lines.High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.Expression of androgen receptors in primary breast cancer.Cisplatin affects the conformation of apo form, not holo form, of BRCA1 RING finger domain and confers thermal stability.Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen.
P2860
Q24294283-BFE83682-B912-4055-8099-25BAF33B70B2Q26775602-5D4FF8B6-9699-462D-9C0A-58D9A08629F2Q27004457-68B050A1-A0D7-467C-B4E0-D48E3C83C322Q28534561-91D342AD-F592-4EF3-A28D-89428ED57044Q30438089-E59F857E-D7F8-49A4-8E07-47C63A609D53Q31073908-4A3F4743-6C32-4104-B770-A1E1961049F7Q33994282-B62F0AA8-91A3-4B09-9E08-C77141917C54Q34049715-2C257AD0-71F0-43CE-8FD8-20C4EA5D0C4EQ34121278-A852F319-2CFB-4BF8-8C03-AFA3B6B7609FQ34162501-BFA541CD-33BB-442C-BA67-54997D7A213EQ34571349-53A280AD-EDDD-474C-8CA2-177F86D2E766Q35550160-E856A756-F9D4-4973-BB1F-9A0D5A393861Q35624809-5DEB78F2-54E4-44F1-B551-45F6036AD9F5Q35889941-7B89874D-F444-411F-A464-F908F3F92A96Q36285897-F0A93BDD-DA2D-4923-86B5-C904CC0F9CCEQ36629854-372064CF-A82E-4490-8DC8-936207BA5107Q37013055-78856743-2043-4FDF-A9C9-2D1CCE711F1FQ37227994-80C07B73-3B58-4489-88B2-CFB2A2B80881Q37295329-DC8F64D4-5407-4EFD-AF7A-169037A070A3Q37355487-3714CE52-8142-4281-987F-8D7AD99E5666Q37360172-13B9C05B-D6D8-4E6B-B155-F386212815D2Q37401138-3BBBD36D-01B4-465A-9EFB-E44C9481692CQ37800039-61FAFF06-148D-432E-B81E-FF600E0B9E79Q37839120-18DBA9CC-47A5-4D5F-9504-D5AD16B0BF20Q37856782-D271764D-25E1-4B9F-A141-3F51479B8CCBQ37894106-4F7A2645-1135-4799-BB89-F9E6EF2788A6Q37976288-F593FA3F-63C6-4CB9-B9E6-859B3118196BQ38007148-3B8DA173-9EF5-484C-BFA8-40183451BD9DQ39355884-381E7DD7-E014-4AFB-9CD4-D7AF5EEA332AQ39425843-F81FCEEF-E7C4-4CA1-B9B7-F29E9D36947AQ39624452-3956E789-FC7F-4F7A-B144-2C9A064A49DDQ39699735-0A1C8898-01FD-424B-BFC2-EFF0A573597EQ42476835-23E72474-278B-4A3F-B72D-080BBF2B28A9Q42479699-501A2054-924D-4D87-9A6D-B5C470CA5B38Q43060762-4292840D-CE8D-4249-BC1C-7B1A69CF5582Q43249156-70F72DC2-5DCF-4352-B86C-99C28B35CC73Q43537472-427C3690-95E5-4C89-94A5-60F5EBF9D390Q51342236-7026CE94-3DB0-4BB2-B440-66228174F99B
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Targeted therapies in breast cancer: where are we now?
@en
Targeted therapies in breast cancer: where are we now?
@nl
type
label
Targeted therapies in breast cancer: where are we now?
@en
Targeted therapies in breast cancer: where are we now?
@nl
prefLabel
Targeted therapies in breast cancer: where are we now?
@en
Targeted therapies in breast cancer: where are we now?
@nl
P1476
Targeted therapies in breast cancer: where are we now?
@en
P2093
José Baselga
P304
P356
10.1016/J.EJCA.2008.09.026
P577
2008-11-14T00:00:00Z